This is a non-material event with no immediate financial impact. Monitor progress of TCR-T clinical development and any future distribution revenue from Malaysia. The 20-F filed concurrently provides more relevant financial context.
Price Chart
Executive Summary
EUDA Health announced that its partner Shenzhen Inno received approval under the Shenzhen Key Industry R&D Program for TCR-T cell therapy development, with potential government funding of up to approximately US$434,688. EUDA holds non-exclusive distribution rights for Malaysia. The funding amount is immaterial to EUDA's financials, and the program runs from 2026 to 2028, so no near-term revenue impact.
Key Facts
- Shenzhen Inno received approval under the 2025 Shenzhen Key Industry R&D Program for TCR-T cell therapy development.
- Potential funding of up to approximately US$434,688 from Shenzhen Science and Technology Innovation Bureau.
- EUDA holds non-exclusive distribution rights to market selected immunotherapies in Malaysia via subsidiary CK Health Plus Sdn Bhd.
- Project implementation period: January 1, 2026 to December 31, 2028.
Financial Impact
Up to $434,688 government funding to partner; no direct revenue to EUDA at this stage.
Risk Factors
- TCR-T therapy may fail in clinical studies, making distribution rights worthless.
- Government funding is contingent on project milestones and may not be fully received.
- Non-exclusive distribution limits EUDA's competitive advantage in Malaysia.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-019415 |
| Document: form6-k.htm | 0001493152-26-019415 |
| Document: 0001493152-26-019415-index-headers.html | 0001493152-26-019415 |
| Document: 0001493152-26-019415-index.html | 0001493152-26-019415 |
| Document: 0001493152-26-019415.txt | 0001493152-26-019415 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $0.0267 $0.0247 | ▼ −7.49% | ▼ −11.11% | — |
Jun 1, 2026 21w ago | 6-K | $0.0460 $0.0239 | ▼ −48.04% | ▼ −46.75% | — |
Jun 1, 2026 21w ago | 6-K | $0.0460 $0.0239 | ▼ −48.04% | ▼ −46.75% | — |
Apr 28, 2026 26w ago | 6-K | $0.0460 $0.0460 | · 0.00% | ▼ −6.05% | — |
Apr 27, 2026 26w ago | 6-K | $0.0460 $0.0336 | ▲ +26.96% | ▲ +31.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers